Publications
Science advancesMar 2024 |
10
(
10
),
eadl1122
DOI:
10.1126/sciadv.adl1122

Coxsackievirus infection induces direct pancreatic β cell killing but poor antiviral CD8+ T cell responses

Vecchio, Federica; Carré, Alexia; Korenkov, Daniil; Zhou, Zhicheng; Apaolaza, Paola; Tuomela, Soile; Burgos-Morales, Orlando; Snowhite, Isaac; Perez-Hernandez, Javier; Brandao, Barbara; Afonso, Georgia; Halliez, Clémentine; Kaddis, John; Kent, Sally C; Nakayama, Maki; Richardson, Sarah J; Vinh, Joelle; Verdier, Yann; Laiho, Jutta; Scharfmann, Raphael; Solimena, Michele; Marinicova, Zuzana; Bismuth, Elise; Lucidarme, Nadine; Sanchez, Janine; Bustamante, Carmen; Gomez, Patricia; Buus, Soren; nPOD-Virus Working Group, ; You, Sylvaine; Pugliese, Alberto; Hyoty, Heikki; Rodriguez-Calvo, Teresa; Flodstrom-Tullberg, Malin; Mallone, Roberto
Product Used
Genes
Abstract
Coxsackievirus B (CVB) infection of pancreatic β cells is associated with β cell autoimmunity and type 1 diabetes. We investigated how CVB affects human β cells and anti-CVB T cell responses. β cells were efficiently infected by CVB in vitro, down-regulated human leukocyte antigen (HLA) class I, and presented few, selected HLA-bound viral peptides. Circulating CD8+ T cells from CVB-seropositive individuals recognized a fraction of these peptides; only another subfraction was targeted by effector/memory T cells that expressed exhaustion marker PD-1. T cells recognizing a CVB epitope cross-reacted with β cell antigen GAD. Infected β cells, which formed filopodia to propagate infection, were more efficiently killed by CVB than by CVB-reactive T cells. Our in vitro and ex vivo data highlight limited CD8+ T cell responses to CVB, supporting the rationale for CVB vaccination trials for type 1 diabetes prevention. CD8+ T cells recognizing structural and nonstructural CVB epitopes provide biomarkers to differentially follow response to infection and vaccination.
Product Used
Genes

Related Publications